Cargando…

Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon

BACKGROUND: The cause and clinical significance of the transient decrease in platelet (PLT) count observed in relapsing remitting multiple sclerosis (RRMS) during alemtuzumab administration remain undefined. The aim of this study was to analyse the kinetics and clinical relevance of early onset thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puthenparampil, Marco, Rinaldi, Francesca, Federle, Lisa, Cazzola, Chiara, Perini, Paola, Gallo, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784536/ https://www.ncbi.nlm.nih.gov/pubmed/29399047 http://dx.doi.org/10.1177/1756285617741056

Ejemplares similares

Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy
por: Rinaldi, Francesca, et al.
Publicado: (2017)

NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2018)

Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2023)

Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis
por: Puthenparampil, Marco, et al.
Publicado: (2020)

Alemtuzumab following natalizumab in highly active paediatric-onset multiple sclerosis
por: Margoni, Monica, et al.
Publicado: (2019)

Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis
por: Miscioscia, Alessandro, et al.
Publicado: (2022)

ODP482 Graves Orbitopathy Secondary to Alemtuzumab Infusion for Multiple Sclerosis
por: Alam, Mustafa, et al.
Publicado: (2022)

BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset
por: Puthenparampil, M., et al.
Publicado: (2017)

Alemtuzumab for Multiple Sclerosis
por: Willis, Mark D., et al.
Publicado: (2016)

Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis
por: Puthenparampil, Marco, et al.
Publicado: (2017)

Alemtuzumab in the treatment of multiple sclerosis
por: Fernandez, Óscar
Publicado: (2014)

Alemtuzumab for the treatment of multiple sclerosis
por: Willis, Mark D, et al.
Publicado: (2015)

Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis
por: Tzanetakos, Dimitrios, et al.
Publicado: (2022)

D-KEFS ST Failure Identifies Multiple Sclerosis Patients With Worse Objective and Self-Perceived Physical and Cognitive Disability
por: Riccardi, Alice, et al.
Publicado: (2019)

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report
por: Myro, Aija Zuleron, et al.
Publicado: (2018)

Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease
por: Miscioscia, Alessandro, et al.
Publicado: (2023)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS
por: Thomas, Katja, et al.
Publicado: (2016)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Role of Monoclonal Antibody "Alemtuzumab" in the Treatment of Multiple Sclerosis
por: Nosher, Sadia, et al.
Publicado: (2021)

Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors
por: Puthenparampil, M., et al.
Publicado: (2021)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Sexual Dysfunction in Multiple Sclerosis: The Role of Executive Function
por: Marinetto, Silvia, et al.
Publicado: (2023)

Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment along Disease Duration
por: Maffezzini, Sabrina, et al.
Publicado: (2023)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij, Rachel, et al.
Publicado: (2015)

Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
por: Dubey, Divyanshu, et al.
Publicado: (2015)

Alemtuzumab in the treatment of multiple sclerosis: patient selection and special considerations
por: Dörr, Jan, et al.
Publicado: (2016)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis
por: Rolla, Simona, et al.
Publicado: (2020)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion
por: Tzartos, John S., et al.
Publicado: (2020)

Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence
por: Signoriello, Elisabetta, et al.
Publicado: (2023)

PLATELETS AND THE SHWARTZMAN PHENOMENON
por: Levin, Jack, et al.
Publicado: (1965)

Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study
por: Riccardi, Alice, et al.
Publicado: (2021)

Alemtuzumab improves contrast sensitivity in patients with relapsing–remitting multiple sclerosis
por: Graves, Jennifer, et al.
Publicado: (2013)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_scb0hmc8l6t5ngrcpukrmnnh1l